Department of DiabetesEndocrinology and Nutrition, Hospital de Sabadell, Corporació Sanitària i Universitària Parc Taulí (Universitat Autònoma de Barcelona), Parc Taul s/n, 08208 Sabadell, SpainCentro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y la Nutrición (CIBERobn)Hospital Clínico Virgen de la Victoria, Málaga, SpainDiabetesEndocrinology and Nutrition Unit, Hospital Sant Joan de Déu de Manresa, Xarxa Assistencial Althaia, Manresa, SpainCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and Diabetes and Metabolism Research UnitInstitut de Recerca Hospital Universitari Vall d'Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, SpainDepartment of DiabetesEndocrinology and Nutrition, Hospital de Sabadell, Corporació Sanitària i Universitària Parc Taulí (Universitat Autònoma de Barcelona), Parc Taul s/n, 08208 Sabadell, SpainCentro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y la Nutrición (CIBERobn)Hospital Clínico Virgen de la Victoria, Málaga, SpainDiabetesEndocrinology and Nutrition Unit, Hospital Sant Joan de Déu de Manresa, Xarxa Assistencial Althaia, Manresa, SpainCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and Diabetes and Metabolism Research UnitInstitut de Recerca Hospital Universitari Vall d'Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain.
Department of DiabetesEndocrinology and Nutrition, Hospital de Sabadell, Corporació Sanitària i Universitària Parc Taulí (Universitat Autònoma de Barcelona), Parc Taul s/n, 08208 Sabadell, SpainCentro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y la Nutrición (CIBERobn)Hospital Clínico Virgen de la Victoria, Málaga, SpainDiabetesEndocrinology and Nutrition Unit, Hospital Sant Joan de Déu de Manresa, Xarxa Assistencial Althaia, Manresa, SpainCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and Diabetes and Metabolism Research UnitInstitut de Recerca Hospital Universitari Vall d'Hebrón (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain.
J Endocrinol. 2014 Jun;221(3):405-13. doi: 10.1530/JOE-13-0407. Epub 2014 Mar 28.
The aim of this study was to investigate the relationship between advanced glycation end products (AGEs) and arterial stiffness (AS) in subjects with type 1 diabetes without clinical cardiovascular events. A set of 68 patients with type 1 diabetes and 68 age- and sex-matched healthy subjects were evaluated. AGEs were assessed using serum concentrations of N-carboxy-methyl-lysine (CML) and using skin autofluorescence. AS was assessed by aortic pulse wave velocity (aPWV), using applanation tonometry. Patients with type 1 diabetes had higher serum concentrations of CML (1.18 vs 0.96 μg/ml; P=0.008) and higher levels of skin autofluorescence (2.10 vs 1.70; P<0.001) compared with controls. These differences remained significant after adjustment for classical cardiovascular risk factors. Skin autofluorescence was positively associated with aPWV in type 1 diabetes (r=0.370; P=0.003). No association was found between CML and aPWV. Skin autofluorescence was independently and significantly associated with aPWV in subjects with type 1 diabetes (β=0.380; P<0.001) after adjustment for classical cardiovascular risk factors. Additional adjustments for HbA1c, disease duration, and low-grade inflammation did not change these results. In conclusion, skin accumulation of autofluorescent AGEs is associated with AS in subjects with type 1 diabetes and no previous cardiovascular events. These findings indicate that determination of tissue AGE accumulation may be a useful marker for AS in type 1 diabetes.
本研究旨在探讨 1 型糖尿病患者中无临床心血管事件的晚期糖基化终产物(AGEs)与动脉僵硬度(AS)之间的关系。评估了一组 68 例 1 型糖尿病患者和 68 例年龄和性别匹配的健康对照者。使用血清 N-羧甲基赖氨酸(CML)浓度和皮肤自发荧光来评估 AGEs。使用平板测压法评估 AS ,即主动脉脉搏波速度(aPWV)。与对照组相比,1 型糖尿病患者的血清 CML 浓度更高(1.18 对 0.96μg/ml;P=0.008),皮肤自发荧光水平更高(2.10 对 1.70;P<0.001)。这些差异在调整了经典心血管危险因素后仍然显著。皮肤自发荧光与 1 型糖尿病患者的 aPWV 呈正相关(r=0.370;P=0.003)。CML 与 aPWV 之间无相关性。在调整了经典心血管危险因素后,皮肤自发荧光与 1 型糖尿病患者的 aPWV 呈独立且显著相关(β=0.380;P<0.001)。进一步调整 HbA1c、病程和低度炎症并未改变这些结果。总之,皮肤中积累的自发荧光 AGEs 与无既往心血管事件的 1 型糖尿病患者的 AS 相关。这些发现表明,组织 AGE 积累的测定可能是 1 型糖尿病中 AS 的有用标志物。